Basilea climbs in premarket on positive results from ERADICATE study

Basilea Pharmaceutica AG, Allschwil

28/06/2022 07:36

** Shares of Basilea Pharmaceutica  BSLN.S  are up 3.1%
premarket after the Swiss biopharma company announced positive
topline results from phase 3 ERADICATE study  urn:newsml:reuters.com:*:nASM000H3H
    ** Multicenter ERADICATE phase 3 study explores ceftobiprole
for treatment of patients with staphylococcus aureus bacteremia
(SAB) that causes bloodstream infections
    ** The company says ceftobiprole met both primary and
secondary efficacy endpoints
    ** It plans to submit a new drug application in United
States around the year end 2022
    ** Basilea shares also rose on Monday after it flagged
progress in the implementation of its strategy to focus on
anti-infectives  urn:newsml:reuters.com:*:nFWN2YC0SX

 (Reporting by Anastasiia Kozlova)
 ((Anastasiia.Kozlova@thomsonreuters.com))